Stock VICORE PHARMA HOLDING AB
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

Vicore Pharma Holding AB Share Price Nasdaq Stockholm

Equities

Biotechnology & Medical Research

End-of-day quote Nasdaq Stockholm
Other stock markets
- SEK - Intraday chart for Vicore Pharma Holding AB
03/05 Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
04/04 Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election CI

Financials

Sales 2024 * 52M 4.81M 401M Sales 2025 * 393M 36.35M 3.03B Capitalization 2.15B 199M 16.58B
Net income 2024 * -221M -20.43M -1.7B Net income 2025 * -166M -15.35M -1.28B EV / Sales 2024 * 35.4 x
Net cash position 2024 * 306M 28.31M 2.36B Net cash position 2025 * 222M 20.51M 1.71B EV / Sales 2025 * 4.9 x
P/E ratio 2024 *
-14.2 x
P/E ratio 2025 *
-8.61 x
Employees -
Yield 2024 *
-
Yield 2025 *
-
Free-Float 86.02%
More Fundamentals * Assessed data

Latest news about Vicore Pharma Holding AB

Vicore Pharma Holding AB Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Vicore Pharma Holding AB Announces Maarten Kraan, as Board Member Declined Re-Election CI
Vicore Announces FDA Breakthrough Device Designation for AlmeeTM, a Digital Therapy for Patients with Pulmonary Fibrosis CI
Vicore Pharma Holding AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Vicore Pharma Holding AB Reports Earnings Results for the Full Year Ended December 31, 2023 CI
Vicore Pharma Signs Licensing Deal for Idiopathic Pulmonary Fibrosis Drug Candidate MT
Alex Therapeutics and Vicore Pharma Announces Positive Results of the COMPANION Study CI
Vicore Pharma Holding AB Confirms IPF Development Program on Track and Provides Early-Stage Pipeline Updates CI
Vicore Pharma Holding AB Appoints Bertil Lindmark as Chief Medical Officer CI
Vicore Pharma Holding AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
Vicore Pharma Holding AB Announces the Nomination Committee for the 2024 Annual General Meeting CI
Vicore Pharma Holding AB Provides Update Regarding Phase 1 Study of C106 CI
Certain Shares of Vicore Pharma Holding AB are subject to a Lock-Up Agreement Ending on 11-SEP-2023. CI
Vicore Pharma's New CEO to Formally Take Office MT
Vicore Pharma Holding AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023 CI
More news

Latest transcript on Vicore Pharma Holding AB

Logo Vicore Pharma Holding AB
Vicore Pharma Holding AB - Special Call
More transcripts

Press releases Vicore Pharma Holding AB

Interim report January-March 2024 AQ
Vicore to Present at Upcoming April 2024 Investor Conferences AQ
Vicore to Present at Upcoming Investor Conferences AQ
Vicore to Present at Upcoming Investor Conferences AQ
Notice of annual general meeting of Vicore Pharma Holding AB (publ) AQ
More press releases

Managers and Directors - Vicore Pharma Holding AB

Managers TitleAgeSince
Ahmed Mousa CEO
 Chief Executive Officer 40 09/23/09
Hans Jeppsson DFI
 Director of Finance/CFO - 01/17/01
Elin Rosendahl CTO
 Chief Tech/Sci/R&D Officer - 16/20/16
Members of the board TitleAgeSince
Jacob Uno Stanley Gunterberg CHM
 Chairman 57 01/18/01
Johannes G. C. P. Schikan BRD
 Director/Board Member 66 01/18/01
Michael Buschle BRD
 Director/Board Member 64 01/23/01
More insiders

Company Profile

Vicore Pharma Holding AB is a Sweden-based drug-development company. The Company's portfolio contains small molecules with potential indications, including anti-inflammation, nerve generation and cardiovascular disease. The Company is a wholly owned subsidiary of Mintage Scientific AB.
Sector
Biotechnology & Medical Research
Calendar
07/05/2024 - Annual General Meeting
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+8.96% 105B
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
-1.43% 104B
ARGENX SE Stock argenx SE
+4.40% 22.94B
BIONTECH SE Stock BioNTech SE
-12.15% 22.34B
GENMAB A/S Stock Genmab A/S
-4.36% 19.25B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-39.98% 17.08B
BEIGENE, LTD. Stock BeiGene, Ltd.
-10.04% 16.96B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+38.61% 12.63B
VIKING THERAPEUTICS, INC. Stock Viking Therapeutics, Inc.
+313.59% 8.49B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. VICO Stock
  4. Stock